

WELCOME LETTER



Dear Friends and Colleagues,

It is with pleasure that I welcome you to Rome for the 5th International Meeting on New Drugs (and New Concepts) in Breast Cancer, bringing together clinicians, mainly medical oncologists, and researchers including this year a substantial translational research component. The issues enlisted in this preliminary program, in particular including data from clinical trials stemming from that original basic research, demonstrate how the translation of basic research into practical clinical tools is particularly active in this disease.

The program has been designed in the pursuit of excellence and, as usually, all lectures will be presented by an international distinguished outstanding faculty who will report all their experiences and developments.

I look forward to joining you and I also hope you can enjoy a unique and pleasant stay in our wonderful City.

Francesco Cognetti

SCIENTIFIC COMMITTEE

P. Conte (Padua, I)
M. De Laurentiis (Naples, I)
S. De Placido (Naples, I)
L. Del Mastro (Genoa, I)
A. Di Leo (Prato, I)
S. Gori (Negrar-VR, I)
P. Pronzato (Genoa, I)

LOCAL SCIENTIFIC COORDINATOR

Alessandra Fabi

LOCAL SCIENTIFIC COMMITTEE

Daniele Alesini
Simona Gasparro
Paola Malaguti

CONGRESS VENUE AND GENERAL INFORMATION

The Scientific Sessions will be held on November 9-10, 2017 at the Regina Elena National Cancer Institute - "Raffaele Bastianelli" Congress Centre (via Fermo Ognibene, 23 - 00144 Rome).

Language

The official language of the Congress is English. Simultaneous translation will not be provided.

Certificate of attendance

Certificates will be issued to all registered participants who will expressly make request at the Secretariat Desk at the end of the Congress.

CME Credits

The Congress will apply for CME Credits.

REGISTRATION INFORMATION

- | | |
|--|-----------------------------|
| · Registration Fee | € 183,00 (VAT 22% included) |
| · Registration for doctors of Regina Elena National Cancer Institute | FREE |
| · Post graduate students | FREE |

The registration fee entitles delegates to the following:

- entry to scientific sessions
- 1 coffee break and 1 buffet lunch on November 9 and 10, 2017
- CME credits
- congress material
- certificate of attendance

For further information or to register please visit the official website:

<http://web.aimgroupinternational.com/2017/breastcancer>

or write to: breastcancer2017@aimgroup.eu

CME PROVIDER

AIM Education - Provider n. 93

Via G. Ripamonti, 129 - 20141 Milan, Italy
Ph. +39 02 56601.1 - Fax +39 02 70048585
cme@aimgroup.eu - www.aimeducation.it

ORGANIZING SECRETARIAT

AIM Group International



Rome Office
Via Flaminia, 1068 - 00189 Rome
Ph. +39 06 33053.1 - Fax +39 06 33053249
breastcancer2017@aimgroup.eu
<http://web.aimgroupinternational.com/2017/breastcancer>

5th International Meeting on New Drugs (and New Concepts) in Breast Cancer

ROME, NOVEMBER 9-10, 2017

Regina Elena National Cancer Institute
Bastianelli Congress Centre

PRESIDENT: *Francesco Cognetti*



**09.00 Lecture**

The tumor microenvironment in breast cancer growth and progression (TBD)

1ST SESSION**HER2 POSITIVE TUMORS**

Chairmen: F. Puglisi, C. Tondini

09.20 New biology concepts (G. Curigliano)

09.40 Optimizing neoadjuvant and adjuvant treatment (H. Burstein)

10.00 When do you add an endocrine drug to the Her2 dual blockade? (TBD)

10.20 Treatment duration of HER2-directed agents in metastatic disease (E. Perez)

10.40 Drug resistance: mechanism and clinical results (M. Scaltriti)

11.00 The use of biosimilars (R. Danesi)

11.20 Coffee Break

2ND SESSION**LUMINAL TUMORS**

Chairmen: S. Gori, G. Tortora

11.30 The intestinal microbiome (F. Scaldaferrì)

11.50 CD4/6 inhibitors: the role in the adjuvant/neoadjuvant setting (M. Cristofanilli)

12.10 New PI3K inhibitors (G. Curigliano)

3RD SESSION**TRIPLE NEGATIVE**

Chairman: G. Mustacchi

12.30 Lecture

Insights into the biology: new molecular classification for identifying immuno therapeutics targets (K. Willard - Gallo)

12.50 New Developments in the Treatment of advanced diseases and biomarkers evidence (M.J. Duffy)

13.10 Neo/adjuvant systemic therapy today (M. Cristofanilli)

13.30 Lunch

4TH SESSION**BRCA AND NEW OPINIONS**

Chairmen: S. Cinieri, L. Del Mastro

14.00 Surgical update in patients with early disease and BRCA mutation (V. Sacchini)

14.20 Novel drugs and new trials in BRCA mutated patients (J. Crown)

14.40 Fertility and BRCA mutation (M. Lambertini)

5TH SESSION**IMMUNOSYSTEM AND IMMUNOTHERAPY**

Chairman: S. De Placido

15.00 Lecture

Immunotherapy: what we still need to know? (E. Perez)

15.20 New immunotargets in breast cancer (G. Bianchini)

15.40 The combination with nanoparticle molecules (M. De Laurentiis)

16.00 Discussion

6TH SESSION**NEW CONCEPTS**

Chairman: E. Bria

16.20 From phase I-III to new clinical trials methodologies in breast cancer (P. Bruzzi)

16.40 Trials on druggable mutations, regulatory implications (S. Vella)

Presenting: P. Giacomini

16.50 Lecture

Precision medicine in breast cancer today (David B. Solit)

FRIDAY, NOVEMBER 10

Presenting: F. Cognetti

Lecture

09.00 Breast cancer chemo-prevention (A. De Censi)

7TH SESSION**SUPPORTIVE CARE AND LIFESTYLE**

Chairmen: V. Adamo, F. Roila

09.20 Toxicity induced by therapy: the new profile of the oncologist (D. Santini)

09.40 Musculoskeletal symptoms induced by aromatase inhibitors: new therapeutic approach (C.L. Loprinzi)

10.00 Low-fat diet: is it really a predictor for the best outcome? (R.T. Chlebowski)

10.20 Physical exercise and breast cancer: risk correlation to subtype and therapeutic effect (D.C. McKenzie)

10.40 Lecture

Adjuvant therapy in HER2 positive early breast cancer: for whom? How long? With what? (P.F. Conte)

11.00 Coffee Break

8TH SESSION**EVOLVING MOLECULES**

Chairman: V. Guarneri

11.10 Etirinotecal pegol: in which position in the future clinical choice? (C.J. Twelves)

11.30 Trop-2: potential target for antibody-drug conjugates (A. Bardia)

9TH SESSION**HORMONAL THERAPY AND NOVEL DISCOVERIES IN DRUG RESISTANCES**

Chairmen: G. Arpino, A. Fabi

11.50 Lecture

Mechanism and clinical results in ER positive patients (A. Di Leo)

12.10 New selective estrogen receptor antagonist (R.S. Finn)

12.30 Lecture

Clinical utility of multigene assays and outcome of disease (TBD)

10TH SESSION**AGE AND BREAST CANCER**

Chairmen: A. Gennari, U. Tirelli

12.50 Evaluation and treatment of older patients (in early stage) (L.M. Repetto)

13.10 The treatment of Metastatic disease in elderly patients, light and shadow (C. Fontanella)

13.30 Discussion and Conclusions

14.00 Lunch